Sterling Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Sterling Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-772	Closed	-$31.1K	–	3290
2026 Q1	$31.1K	Hold	772	–	–	﹤0.01%	1829
2025 Q4	$19.4K	Buy	772 +608	+371%	+$14.3K	﹤0.01%	2246
2025 Q3	$3.71K	Sell	164 -1	-0.6%	-$23	﹤0.01%	2850
2025 Q2	$2.86K	Sell	165 -194	-54%	-$3.59K	﹤0.01%	2806
2025 Q1	$7.85K	Sell	359 -1,328	-79%	-$36.7K	﹤0.01%	1956
2024 Q4	$53.8K	Sell	1,687 -211	-11%	-$6.34K	﹤0.01%	1588
2024 Q3	$54.7K	Buy	+1,898	New	+$70.3K	﹤0.01%	1442

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sterling Capital Management's APLS Position: Q2 2026 in Review

Sterling Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 772 shares — an estimated $31.1K sold.

Sterling Capital Management first reported a position in APLS in Q3 2024 and held it in 7 quarters. The position peaked at $54.7K in Q3 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Sterling Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sterling Capital Management sold 772 Apellis Pharmaceuticals shares in Q2 2026, an estimated $31.1K.
Sterling Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 7 quarters.
Sterling Capital Management's Apellis Pharmaceuticals position peaked at $54.7K in Q3 2024.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.